Citations for
Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.
Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, Lau SH, Li Y, Li Y, Guan XY.
Hepatology 51(4):1255-63.PMID: 20112425 2010
Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma.
Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, Dong S, Guan XY, Poon RT, Luk JM.
Int J Cancer 127(4):968-76.PMID: 19998337 2010
Crystal structure of human eIF5A1: insight into functional similarity of human eIF5A1 and eIF5A2.
Tong Y, Park I, Hong BS, Nedyalkova L, Tempel W, Park HW.
Proteins 75(4):1040-5. No abstract available. PMID: 19280598 2009
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.
Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW.
Cell 135(5):852-64. Epub 2008 Nov 13.PMID: 19012953 2008
Identification and characterization of eukaryotic initiation factor 5A-2.
Clement PM, Henderson CA, Jenkins ZA, Smit-McBride Z, Wolff EC, Hershey JW, Park MH, Johansson HE.
Eur J Biochem 270(21):4254-63. 2003
Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression.
Jenkins ZA, Haag PG, Johansson HE.
Genomics 71(1):101-9. 2001
Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer.
Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM.
Cancer Res 61(9):3806-9. 2001